Global
CURRENT LOCATION: HOME > Global > Europe
Global
Adhere to the strategy of R&D innovation and international expansion; accelerate the research and development of innovative drug projects in core areas; promote the development and listing of characteristic generic drugs around product lines; continuously enrich the product lines; actively expand mature markets in Europe and the United States, as well as emerging markets in Africa, Central Asia and Southeast Asia.
ASIA PACIFIC

Humanwell is one of China's leading pharmaceutical companies, competing with both domestic and multinational corporations. We have established dominant market positions in several therapeutic areas: over 60% market share in anesthetics/analgesics and more than 50% in Uyghur medicine (one subset of Chinese traditional medicine), making us the undisputed leader in these market segments. We also command a leading position in fertility regulation drugs with over 30% market share. Through our expanding portfolio of high-value products, we are steadily progressing toward our goal of remaining a top pharmaceutical company in China.


Our robust commercial infrastructure with a professional sales team of 6,000 representatives, enables comprehensive market coverage across China. Our extensive distribution network reaches 10,000 hospitals and 30,000 pharmacies nationwide.


NORTH AMERICA

Humanwell’s North American expansion started in 2008, with the establishment of PuraCap Pharmaceutical in New Jersey. PuraCap specializes in research and development, manufacturing, and commercialization of soft gel prescription generic and OTC products. With its headquarters, R&D team, and sales and marketing team in New Jersey, its state-of-the-art cGMP manufacturing facility (soft gel capacity of up to 6 billion capsules annually) in Wuhan, and expansion to 12 billion capsules annually in next few years, and total employees of 500+, PuraCap supplies major US wholesalers and pharmacy chains with more than 200 products carrying major and store brands.

Humanwell acquired Epic Pharma, LLC in 2016. Epic is a leader in R&D, manufacturing, and commercialization of diversity dosage form products and controlled substance prescription generics drugs in the US. Located in New York with 230 employees, Epic manufactures high quality prescription generics on behalf of its pharmaceutical clients such as Sandoz, and supplies to major wholesalers and group purchase organizations (GPOs) prescription generics under its own label. In addition to a total of 40 marketed products, the company owns a pipeline with 230 ANDAs, 12 filed to the FDA with pending approvals, and 10 in late stage development.


AFRICA

Humanwell expanded its presence into Africa to provide equitable healthcare solutions to a region with tremendous un